Skip to main content
. Author manuscript; available in PMC: 2014 Apr 17.
Published in final edited form as: Bioconjug Chem. 2013 Mar 18;24(4):669–677. doi: 10.1021/bc300640j

Figure 2.

Figure 2

Cellular uptake of (A) targeted MAP-CPT nanoparticles at increasing ratio of Herceptin-PEG-nitroPBA to nanoparticle in BT-474, (B) medium MAP-CPT nanoparticles or targeted MAP-CPT nanoparticles with or without free Herceptin (10 mg/ml) in BT-474 and MCF-7 cell lines.